As clinical trials in oncology try to incorporate technology more efficiently in their day-to-day operations, its uniform implementation across study sites continues to be a challenge. Clinical sites use disparate methods of record-keeping and allowing those to use one cohesive method is critical but demanding.

In a recent discussion on this topic, Axiom Real-Time Metrics’ director of project management Quinn Zarubick emphasised the need to collaborate early with key opinion leaders at clinical sites to understand the feasibility of implementing a unified platform. In a discussion at Arena International’s Clinical Operations in Oncology Trials 2021 virtual conference held in June, Zarubick said this would allow the study to take a per-site approach, but at the same time make it as streamlined as possible.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The main advantage with using a unified platform is to avoid the need for reconciliation at the end of the study, said Axiom’s associate director for RTSM/IWRS Heather DiFruscia. If everything is completed in real-time, that sets the study up for success and the sites for a clean close-out, she added.

To watch the full presentation and see more clinical trials events please click here.